托拉塞米联合比索洛尔对原发性高血压合并收缩性心力衰竭患者的影响及不良反应分析

中国药物警戒 ›› 2019, Vol. 16 ›› Issue (8): 467-472.

托拉塞米联合比索洛尔对原发性高血压合并收缩性心力衰竭患者的影响及不良反应分析

张生长¹, 黄伟剑^2,*

1 温州医科大学附属乐清医院心内科,浙江温州 325600;
2 温州医科大学附属第一医院心内科,浙江温州 325000

收稿日期:2019-09-09 修回日期:2019-09-09 出版日期:2019-08-20 发布日期:2019-09-09
通讯作者: *黄伟剑,男,教授,主任医师,心血管各种疑难及重症疾病诊治。E-mail：zhangseptember@yeah.net
作者简介:张生长,男,本科,主治医师,冠心病诊治。

Clinical Efficacy and Adverse Reaction of Torasemide Combined with Bisoprolol in the Treatment of Patients with Essential Hypertension Complicated with Systolic Heart Failure

ZHANG Shengzhang¹, HUANG Weijian^2,*

1 Department of Cardiology, Leqing Hospital Affiliated to Wenzhou Medical University, Zhejiang Wenzhou 325600 China;
2 Department of Cardiology, The First Affiliated Hospital of Wenzhou Medical University, Zhejiang Wenzhou 325000 China

Received:2019-09-09 Revised:2019-09-09 Online:2019-08-20 Published:2019-09-09

摘要/Abstract

摘要： 目的研究托拉塞米联合比索洛尔对原发性高血压合并收缩性心力衰竭患者的影响及不良反应分析。方法选取2016年5月~2018年6月本院收治的134例原发性高血压合并收缩性心力衰竭患者为研究对象,按照随机数表法分组,对照组（托拉塞米治疗）67例、研究组（托拉塞米联合比索洛尔治疗）67例。对比两组治疗前后血压、心功能、生化指标、临床疗效及不良反应发生情况。结果研究组治疗总有效率（95.52%）显著高于对照组（80.60%）,差异有统计学意义（P <0.05）。两组治疗前后收缩压、舒张压及24 h血压变异值组内比较均有明显差异（P <0.05）;治疗后组间比较,研究组收缩压、舒张压及24 h血压变异值均明显低于对照组,差异有统计学意义（P <0.05）。治疗前后组内比较,两组左室舒张末期内径（LVEDD）、左室收缩末期内径（LVESD）及心率较治疗前明显下降,左室射血分数（LVEF）明显升高,差异有统计学意义（P <0.05）;而治疗后组间比较,研究组LVEDD、LVESD及心率明显低于对照组,LVEF明显高于对照组,差异有统计学意义（P <0.05）。组内治疗前后比较,超氧化物歧化酶（SOD）明显升高,丙二醛（MDA）、脑钠肽（BNP）明显下降,差异显著（P <0.05）;治疗后组间比较,研究组SOD明显高于对照组,MDA、BNP明显低于对照组,差异有统计学意义（P <0.05）。不良反应发生率（8.96% vs 11.94%）比较无明显差异（P >0.05）。结论托拉塞米联合比索洛尔对原发性高血压合并心力衰竭的疗效确切,更有助于改善患者心功能状况,稳定血压,抑制氧化应激,不良反应发生率低,安全性较高。

关键词: 托拉塞米, 比索洛尔, 原发性高血压, 心力衰竭

Abstract: Objective To study the clinical efficacy of torasemide combined with bisoprolol in the treatment of patients with essential hypertension complicated with systolic heart failure. Methods 134 patients with essential hypertension and systolic heart failure admitted to our hospital from May 2016 to June 2018 were enrolled in the study. According to the random number table method, control group (torasemide treatment) 67 cases and study group (torasemide combined with bisoprolol treatment) 67 cases. Blood pressure, cardiac function, biochemical parameters, clinical efficacy and adverse reactions were compared before and after treatment. Results The total effective rate of treatment in the study group (95.52%) was significantly higher than the control group (80.60%), and the difference was statistically significant (P <0.05). Before and after treatment, the systolic blood pressure, diastolic blood pressure and 24 h blood pressure variability were significantly different (P<0.05). After treatment, the systolic blood pressure, diastolic blood pressure and 24 h blood pressure variability of the study group were significantly lower than the control group, the difference was statistically significant (P<0.05). Before and after treatment, the left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD) and heart rate were significantly lower than those before treatment, and left ventricular ejection fraction (LVEF) was significantly increased. The difference was statistically significant (P<0.05). Compared with the control group, the LVEDD, LVESD and heart rate in the study group were significantly lower than those in the control group, and the difference was statistically significant (P<0.05). Compared with before and after treatment, superoxide dismutase (SOD) was significantly increased, malondialdehyde (MDA) and brain natriuretic peptide (BNP) were significantly decreased (P<0.05). After treatment, the SOD of the study group was significantly higher than the control group, and the MDA and BNP were significantly lower than the control group (P<0.05). The incidence of adverse reactions (8.96% vs 11.94%) was not significantly different (P>0.05). Conclusion Torasemide combined with bisoprolol is effective in the treatment of essential hypertension complicated with heart failure. It is also helpful to improve cardiac function, stabilize blood pressure, inhibit oxidative stress, and have low incidence of adverse reactions and higher safety.

Key words: torasemide, bisoprolol, essential hypertension, heart failure

中图分类号:

R994.11

张生长, 黄伟剑. 托拉塞米联合比索洛尔对原发性高血压合并收缩性心力衰竭患者的影响及不良反应分析[J]. 中国药物警戒, 2019, 16(8): 467-472.

ZHANG Shengzhang, HUANG Weijian. Clinical Efficacy and Adverse Reaction of Torasemide Combined with Bisoprolol in the Treatment of Patients with Essential Hypertension Complicated with Systolic Heart Failure[J]. Chinese Journal of Pharmacovigilance, 2019, 16(8): 467-472.

参考文献

[1] Walker A M, Patel P A, Rajwani A, et al.Diabetes mellitus is associated with adverse structural and functional cardiac remodelling in chronic heart failure with reduced ejection fraction[J]. Diab Vasc Dis Res, 2016, 13(5): 331-340.
[2] 靳新民. 二甲双胍对高血压合并2型糖尿病患者心室重塑的影响[J]. 中国药物警戒, 2016, 13(1):9-12.
[3] 黄莹, 姚汉玲, 黄 . 托拉塞米治疗AECOPD患者心力衰竭的临床疗效及安全性分析[J].中国医院药学杂志, 2018, 38(18):1964-1966.
[4] 王和银, 谭咏梅, 张兴展, 等.比索洛尔与美托洛尔对原发性高血压患者心率、心率变异性和临床事件的影响[J]. 中华高血压杂志, 2014, 22(2):184-186.
[5] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南[J]. 中华心血管病杂志, 2014, 42(2): 98-122.
[6] 周海蓉, 段学燕, 赵力敏, 等. 托拉塞米联合环磷腺苷葡胺治疗老年慢性心功能不全的应用价值[J]. 中国老年学杂志, 2018, 38(18):4374-4376.
[7] Makoto S, Kazuaki N, Thomas H M.Meta-Analysis of Risks for Short-Term Readmission in Patients With Heart Failure[J]. Am J Cardiol, 2016,117(4): 626-632.
[8] Bart omiej P, Martyna O, Agnieszka S, et al. Central Chemoreceptor Sensitivity Is Not Enhanced in Contemp- orary Patients With Chronic Systolic Heart Failure Receiving Optimal Treatment[J]. J Card Fail, 2017, 23(1): 83-87.
[9] Allida S M, Inglis S C, Davidson P M, et al.Thirst in chronic heart failure: a review[J]. J Clin Nurs, 2015, 24(7/8): 916-926.
[10] 陈端, 侯伟宁, 钟世勤, 等.替米沙坦对使用美托洛尔治疗的慢性心力衰竭合并高血压、糖耐量受损患者糖代谢的影响研究[J]. 实用心脑肺血管病杂志, 2014, 22(8):14-16.
[11] 吴锦波, 叶小汉, 冼绍祥, 等.比索洛尔对心力衰竭大鼠心肌肌浆网钙三磷酸腺苷酶2a活性的影响[J].中华高血压杂志, 2017, 25(6):560-564.
[12] Kassandra S T, Guy L O, Charles E M, et al.Translation of Cardiac Myosin Activation With 2-Deoxy-ATP to Treat Heart Failure Via an Experimental Ribonucleotide Reductase-Based Gene Therapy[J]. JACC: Basic to Transl -ational Science, 2016, 1(7): 666-679.
[13] 吴锦波, 叶小汉, 冼绍祥, 等. 比索洛尔对心力衰竭大鼠心肌肌浆网钙ATP酶2a活性的影响[J]. 临床心血管病杂志, 2017, 33(1):86-91.
[14] Skrabal F, Pichler G P, Gratze G, et al.Adding "hemodynamic and fluid leads" to the ECG. Part I:the electrical estimation of BNP,chronic heart failure (CHF) and extracellular fluid (ECF) accumulation[J]. Med Engineer Phys, 2014, 36(7):896-904.
[15] Nokamura K, Miura D, Matsubara H, et al.Oxidative stress and calcium overload in heart failure[J]. Folia Pharmacologica Japonica, 2012, 140(6):265-269.
[16] 郭丽, 张丽, 邓萌. 比索洛尔对心力衰竭大鼠氧化应激及细胞凋亡的影响[J]. 中国老年学杂志, 2017, 37(20): 4999-5000.